Experimental Drug for Hodgkin's Lymphoma


A new experimental drug for Hodgkin's Lymphoma is showing promise:

"An experimental drug for Hodgkin’s lymphoma, studied at the University of Alabama at Birmingham, showed beneficial effects in stopping tumor growth with moderate side-effects, according to findings published Thursday in the New England Journal of Medicine.

The Phase 1 trial was designed to establish a maximum tolerated dose of brentuximab vedotin (SGN-35), a combination of the monoclonal antibody cAC10 and an antitubulin agent, monomethyl auristatin E (MMAE), developed by Seattle Genetics. Using a dose-escalating protocol, the researchers administered a dose of 0.1 to 3.6 mg per kilogram of body weight.

“Our primary goal was to establish the maximum tolerated dose, one that would not cause adverse side effects of SGN-35,” said Andres Forero-Torres, M.D., an associate scientist in the UAB Comprehensive Cancer Center and a senior author of the study. “In the process, we were pleased to discover that positive responses were observed in 17 of the 45 patients involved in the study, including 11 complete remissions.”"

Read More: http://www.newswise.com/articles/view/570420

LymphomaInfo Social